-+ 0.00%
-+ 0.00%
-+ 0.00%

Xtant Medical Q2 FY26 turns to net loss of $9.41 million; revenue drops 34.96% to $23.03 million

PUBT·08/11/2026 11:04:09
Listen to the news
Xtant Medical Q2 FY26 turns to net loss of $9.41 million; revenue drops 34.96% to $23.03 million
  • Xtant Medical posted Q2 revenue of $23 million, down from $35.4 million a year earlier on divestitures and no license revenue.
  • Net results swung to a loss of $9.4 million, or $0.07 per share, from profit of $3.6 million, or $0.03 per share.
  • Gross margin fell to 57.9% from 68.6%, hit by the end of high-margin Q-code license revenue and inventory charges.
  • Non-GAAP adjusted EBITDA swung to a loss of $2.7 million from a gain of $6.9 million, reflecting a $5 million Dilon exclusivity fee.
  • Signed an exclusive U.S. distribution deal for Dilon’s HEMOBLAST Bellows, hiring its 20-person sales team; launched Trivium Shaped; cut 2026 revenue outlook to $99 million-$103 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtant Medical Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA23588) on August 11, 2026, and is solely responsible for the information contained therein.